EGFR and head and neck squamous cell carcinoma: EGFR expression alone is not sufficient to predict the response to EGFR-kinase inhibitors and activating EGFR kinase mutations are extremely rare in HNSCC [3], thus making the underlying mechanism for the differential sensitivity of HNSCC cells to EGFR inhibitors yet to be elucidated.